Pharmacology of SGLT2 Inhibitors and sGC Stimulators

Overview of Sodium Glucose Co-Transporter Type 2 (SGLT2) Inhibitors

• Definition and Impact: Sodium Glucose Co-Transporter Type 2 inhibitors, commonly referred to as SGLT2 inhibitors, are a class of medications that are fundamentally changing clinical management strategies for patients with heart failure.

• Primary Medications in the Class:

  • Dapagliflozin: Distinguished as the first SGLT2 inhibitor officially indicated for heart failure treatment; serves as the primary focus of pharmacological study.

  • Empeglozin.

  • Eltutriflosin.

• Historical Discovery and Context:

  • Original Indication: These drugs were initially developed and approved for managing Type 2 Diabetes.

  • Accidental Discovery: Their utility in heart failure was identified unintentionally during cardiovascular safety studies.

  • Regulatory Precedent: Previously, a different class of diabetes drugs known as thiazolidinediones (specifically rosiglitazone) was found to cause or worsen heart failure.

  • Safety Trials: To ensure SGLT2 inhibitors did not pose similar risks, intensive cardiovascular safety studies were mandated. These studies revealed a significant, positive "roll on effect" on the cardiovascular system, rather than the expected adverse effects.

• Heart Failure Classifications Treated:

  • Heart failure with reduced ejection fraction (HFrEF).

  • Heart failure with preserved ejection fraction (HFpEF).

  • Heart failure with mid-range ejection fraction (HFmrEF).

Pharmacological Mechanism and Indicators of Dapagliflozin

• Anatomical Target: The drug specifically targets the SGLT2 transporter protein located within the proximal tubules of the kidney.

• Physiological Function and Inhibition:

  • Normal Physiology: Under standard conditions, the SGLT2 transporter reabsorbs glucose from the tubular lumen back into the systemic circulation.

  • Mechanism of Action: Dapagliflozin inhibits this transporter, preventing the reabsorption of both sodium ($Na^+$) and glucose ($C_6H_{12}O_6$) ions.

  • Glycemic Control: This leads to the excretion of glucose into the urine (glycosuria), which provides therapeutic benefits for blood sugar regulation in Type 2 Diabetes patients.

• Mechanism of Osmotic Diuresis:

  • Osmosis Pathway: As sodium ($Na^+$) and glucose ($C_6H_{12}O_6$) are filtered and excreted, water follows these solutes due to the concentration gradient created via osmosis.

  • Outcome: This produces a mild osmotic diuretic effect.

  • Classification Note: Despite this effect, dapagliflozin is not pharmacologically classified as a diuretic medication.

Hemodynamic and Pathophysiological Effects on Heart Failure

• Influence on Preload and Afterload:

  • Reduction of Plasma Volume: The increased excretion of water reduces total plasma volume, which directly decreases cardiac preload.

  • Vascular Tone Reduction: The depletion of sodium ($Na^+$) ions creates a "knock on effect" on calcium ($Ca^{2+}$) channels. Without sufficient calcium stimulation in the vascular smooth muscle, contraction is inhibited, leading to decreased vascular tone and a subsequent reduction in cardiac afterload.

• Sympathetic Nervous System (SNS) Downregulation:

  • Significance: This is identified as the most critical mechanism of action for dapagliflozin in the context of heart failure.

  • Pathophysiological Context: Heart failure progression is largely driven by the chronic overactivation of the SNS.

  • Negative Effects of SNS Activation:

    • Stimulation of the Renin-Angiotensin System (RAS).

    • Elevation of heart rate.

    • Induction of myocardial hypertrophy.

    • Promotion of adverse cardiac remodeling.

  • Drug Counteraction: Dapagliflozin helps stabilize the patient by downregulating this sympathetic activity.

• Metabolic Shifts: The medication optimizes cardiac performance by shifting metabolism toward a more oxygen-efficient energy source.

• Clinical Outcomes for HFrEF: Treatment leads to decreased morbidity and a reduction in the risk of cardiovascular-related death (mortality).

Adverse Effects and Complications of SGLT2 Inhibitor Therapy

• Polyuria and Glycosuria:

  • Condition: Patients experience excessive urine excretion (polyuria).

  • Substances Excreted: By blocking the SGLT2 transporter, the drug causes the excretion of multiple sugars, including glucose, fructose, galactose, and lactose.

• Urinary Tract Infections (UTI):

  • Mechanism: High concentrations of sugars collect in the bladder before excretion. Glucose serves as a primary carbon source for bacterial proliferation.

  • Infection Risk: High sugar levels facilitate infections throughout the urinary tract if bacteria are introduced.

  • Specific Note: The transcript attributes this risk as being "due to surreal."

• Euglycemic Diabetic Ketoacidosis (UDKA):

  • Definition: A condition where acidic ketone bodies accumulate in the systemic circulation despite blood glucose levels appearing relatively normal.

  • High-Risk Patient Groups: Individuals taking exogenous insulin who miss doses, pregnant patients, and patients who are fasting.

Pathophysiology of UDKA Facilitated by Dapagliflozin

• Normal Hormonal Regulation:

  • Beta Cells: Secrete insulin to lower blood glucose.

  • Alpha Cells: Secrete glucagon to raise blood glucose.

  • Beta Oxidation: These hormones regulate the conversion of fatty acids into Acetyl Coenzyme A (Acetyl-CoA) for the Krebs cycle. Normally, only a minimal amount of Acetyl-CoA is converted to ketone bodies.

• Induction by Dapagliflozin:

  • Insulin Suppression: By promoting glycosuria, the drug lowers systemic glucose, removing the trigger for beta cells to secrete insulin.

  • Glucagon Elevation: In response to perceived low blood sugar, alpha cells increase glucagon secretion.

  • Fatty Acid Oxidation: Elevated glucagon levels accelerate fatty acid oxidation, resulting in an accumulation of Acetyl-CoA that exceeds the processing capacity of the Krebs cycle.

  • Ketogenesis: To manage excess Acetyl-CoA, the body shifts to forming ketone bodies. These bodies are acidic, water-soluble, and enter the systemic circulation.

• Clinical Symptoms of Ketoacidosis:

  • Breath: A distinct "fruity smell" caused by the chemical acetone.

  • Physical State: Patients may report feeling "unsteady" or having "slight breath."

Soluble Guanylate Cyclase (sGC) Stimulators: Vericiguat

• Introduction: Vericiguat represents a relatively new medication class, entering the market at the end of 2023.

• Relationship Between sGC and Nitric Oxide (NO):

  • Function of sGC: An enzyme responsible for regulating the biological actions of Nitric Oxide (NO).

  • Role of Nitric Oxide: An endogenous ligand that increases blood flow, lowers blood pressure through ventricular relaxation, and facilitates vasodilation.

  • Enzyme Structure: sGC is composed of alpha ($\alpha$) and beta ($\beta$) subunits.

  • Activation Process: Nitric Oxide binds to the enzyme, and iron simultaneously activates it. This converts Guanosine Triphosphate (GTP) into cyclic Guanosine Monophosphate (cGMP).

  • Signaling Pathway: $GTP \rightarrow \text{cyclic GMP} \rightarrow \text{Binding to Protein Kinase G (PKG)} \rightarrow \text{Relaxation/Vasodilation}$.

Clinical Benefits and Mechanism of Action for Vericiguat

• Impact of Heart Failure on the sGC Pathway:

  • Oxidative Stress: HF triggers inflammatory and oxidative stress, decreasing Nitric Oxide bioavailability.

  • Result: Less GTP is converted to cGMP, leading to decreased coronary blood flow, impaired vasodilation, and poor ventricular relaxation.

• Vericiguat Mechanism:

  • The drug binds directly to the alpha subunit ($\alpha$) of the sGC enzyme.

  • It increases the enzyme's sensitivity to existing Nitric Oxide.

  • It utilizes iron to activate the enzyme and boost the conversion of GTP to cGMP.

• Physiological Benefits:

  • Promotion of ventricular relaxation.

  • Increased coronary blood flow.

  • Reduction of myocardial fibrosis.

  • Inhibition of cardiac remodeling and hypertrophy.

  • Enhanced dilation in peripheral blood vessels.

  • Renal protective effects.

• Clinical Indications: Used for HFrEF to improve cardiac function, mitigate symptoms, and reduce overall cardiovascular risk.

Adverse Effects, Hematology, and Interactions of Vericiguat

• Hypotension: Vasodilatory effects can cause low blood pressure, though orthostatic hypotension is unlikely due to the specific mechanism of cardiac muscle relaxation.

• Drug-Induced Anemia:

  • Hematological Pathway: $\text{Hematopoietic stem cells} \rightarrow \text{Common myeloid progenitor cells} \rightarrow \text{Megakaryocyte erythroid progenitor cells}$.

  • Normal Function: Megakaryocyte erythroid progenitor cells proliferate into erythrocytes (red blood cells) and platelets.

  • Interference Mechanism: Vericiguat increases cGMP in the bone marrow. Excessive cGMP synthesized during this stage decreases the production of megakaryocyte erythroid progenitor cells, leading to a drop in erythrocyte production.

• Teratogenic Risks: Current research suggests potential harm to embryos. Caution is advised as it is not yet fully confirmed if the drug is strictly teratogenic.

• Drug Interactions and Support:

  • Iron Supplements: Iron polymaltose should be co-administered for patients with iron deficiency, as sGC requires iron for stimulation.

  • Side Effect Mitigation: Co-administration of iron or folic acid may minimize the severity of induced anemia.

Administrative Details

• Subject: Pharmacology A

• Date: Saturday, 30 May 2026

• Time: 11:28 AM